

(10) International Publication Number
WO 2012/169863 A3(43) International Publication Date
13 December 2012 (13.12.2012)

(51) International Patent Classification:

C07D 307/46 (2006.01) **A61P 3/00** (2006.01)
C07D 307/54 (2006.01) **A61P 9/00** (2006.01)
A61K 31/341 (2006.01)

(21) International Application Number:

PCT/KR2012/004602

(22) International Filing Date:

11 June 2012 (11.06.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2011-0056060 10 June 2011 (10.06.2011) KR
 10-2012-0062049 11 June 2012 (11.06.2012) KR

(71) Applicant (for all designated States except US): **SK BIO-PHARMACEUTICALS CO., LTD.** [KR/KR]; 99, Seorin-dong, Jongro-gu, Seoul 110-728 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHUNG, Coo-Min** [KR/KR]; c/o SK Biopharmaceuticals Co., Ltd., Research Institute of Bioscience, 325 Expo-ro, Yuseong-gu, Daejeon 305-721 (KR). **RYU, Choon-Ho** [KR/KR]; c/o SK Biopharmaceuticals Co., Ltd., Research Institute of Bioscience, 325 Expo-ro, Yuseong-gu, Daejeon 305-712 (KR). **LEE, Yoon-Kyeong** [KR/KR]; 115-1602, Samsung Raemian Apt., Guro 3-dong, Guro-gu, Seoul 152-767 (KR). **MOON, Jin-Sook** [KR/KR]; #523, Hangrimgwang A dong, Busan National Univ. School of Medicine, Beomeo-ri, Mulgeum-eup, Yangsan-si, Gyeongsangnam-do 626-870 (KR). **LEE, Hye-Sung** [KR/KR]; New renewable Energy Lab, SK Innovation Energy Laboratory, 325 Expo-ro, Yuseong-gu, Daejeon 305-712 (KR). **LEE, Seon-Jeong** [KR/KR]; c/o SK Biopharmaceuticals Co., Ltd., Research Institute of Bioscience, 325 Expo-ro, Yuseong-gu, Daejeon 305-712 (KR). **OH, Kyung-Seok** [KR/KR]; c/o

SK Biopharmaceuticals Co., Ltd., Research Institute of Bioscience, 325 Expo-ro, Yuseong-gu, Daejeon 305-712 (KR).

(74) Agent: **YOU ME PATENT AND LAW FIRM**; Seolim Bldg., 649-10 Yoksam-dong, Kangnam-Ku, Seoul 135-080 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

14 March 2013

(54) Title: 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF

(57) Abstract: Provided are a novel derivative of 5-carbamoyl adamantan-2-yl amide or a pharmaceutically acceptable salt thereof, and a pharmaceutical use thereof for inhibiting the activity of 11 β -hydroxysteroid dehydrogenase type1 (11b-HSD1) or for preventing and/or treating various diseases mediated by 11 β -hydroxysteroid dehydrogenase type1.



WO 2012/169863 A3

A. CLASSIFICATION OF SUBJECT MATTER*C07D 307/46(2006.01)i, C07D 307/54(2006.01)i, A61K 31/341(2006.01)i, A61P 3/00(2006.01)i, A61P 9/00(2006.01)i*

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D 307/46; C07D 451/02; A61K 31/35; A61K 31/505; A61K 31/56; A61K 31/46; C07D 405/12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) & Keywords: carbamoyl, adamantan, HSD1

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2011-068927 A2 (ABBOTT LABORATORIES et al.) 09 June 2011 See document	1-14, 18-23
A	WO 2011-059021 A1 (DAINIPPON SUMITOMO PHARMA CO., LTD. et al.) 19 May 2011 See document	1-14, 18-23
A	WO 2011-049520 A1 (ASTRAZENECA AB et al.) 28 April 2011 See document	1-14, 18-23



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

28 DECEMBER 2012 (28.12.2012)

Date of mailing of the international search report

03 JANUARY 2013 (03.01.2013)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
189 Cheongsu-ro, Seo-gu, Daejeon Metropolitan
City, 302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

CHOI, Won Chul

Telephone No. 82-42-481-5578



INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR2012/004602**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 15-17
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 15-17 pertain to methods for treatment of the human body by therapy, as well as diagnostic methods, and thus relate to a subject matter which this International Searching Authority is not required to search under Article 17(2)(a)(i) and Rule 39.1(iv) of the Regulations under the PCT.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR2012/004602

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2011-068927 A2	09.06.2011	US 2011-0159005 A1 WO 2011-068927 A3	30.06.2011 13.10.2011
WO 2011-059021 A1	19.05.2011	CA 2778175 A1 CN 102596949 A EP 2500345 A1 KR 10-2012-0092150 A TW 201127380 A US 2012-0225876 A1	19.05.2011 18.07.2012 19.09.2012 20.08.2012 16.08.2011 06.09.2012
WO 2011-049520 A1	28.04.2011	AR078673A1 TW 201118085 A US 2011-0092526 A1 UY32954A	23.11.2011 01.06.2011 21.04.2011 31.05.2011